PIPE-307 demonstrated an acceptable safety and tolerability profile PIPE-307 treatment did not result in a significant change in binocular 2.5% low contrast letter acuity (LCLA) SAN DIEGO / Nov 20, 2025 / Business Wire / Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or...Read more
CAREFNDR underscores the potential clinical value of paltusotine beyond acromegaly, and demonstrates progress in Crinetics’ commitment to addressing unmet needs in the neuroendocrine tumor community SAN DIEGO, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals,...Read more
Evidence of Monotherapy Activity: Partial response observed in a MEK-rechallenge 3rd-line melanoma patient with BRAF V600E mutation who remains on trial for more than 11 months A second MEK-rechallenge 3rd-line melanoma patient with BRAF V600E mutation has achieved stable...Read more
RICHMOND, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has accepted Sangamo’s request for a rolling submission and review of the Biologics License Application (BLA)...Read more
FDA Response Streamlines Path to Commercial Production of PF614 SAN DIEGO, CA / ACCESS Newswire / November 20, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation pain and central nervous system...Read more
Following Priority Review, the U.S. FDA granted HYRNUO® (sevabertinib) approval for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by...Read more
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including a small-molecule GLP-1 receptor...
CLICK TO LEARN MORE| Company | Change | Last Trade |
|---|---|---|
| Eli Lilly | 13.91 1.33 | $1,057.20 |
| Insulet | 9.71 3.10 | $322.60 |
| IDEXX Laboratories | 9.61 1.39 | $698.96 |
| Mettler-Toledo | 8.44 0.60 | $1,407.85 |
| Madrigal Pharmaceuticals | 7.73 1.43 | $549.85 |
| Movano Health | 6.58 211.58 | $9.69 |
| Regeneron Pharmaceuticals | 6.08 0.82 | $743.08 |
| Chemed | 5.82 1.36 | $435.15 |
| Vertex Pharmaceuticals | 5.48 1.30 | $427.80 |
| HCA Healthcare | 5.34 1.12 | $481.62 |
| Stryker | 4.82 1.34 | $365.30 |
| West Pharmaceutical | 4.74 1.84 | $262.51 |
| Bio-Rad Laboratories | 4.65 1.53 | $308.26 |
| AbbVie | 4.52 1.97 | $233.97 |
| Univerl Health Services | 3.86 1.71 | $229.24 |
| Penumbra | 3.75 1.34 | $283.54 |
| Waters | 3.68 0.97 | $382.30 |
| Cigna | 3.51 1.30 | $273.11 |
| Company | Volume | Last Trade |
|---|---|---|
| Sangamo Therapeutics | 36,957,595 | $0.43 |
| Telomir Pharmaceuticals | 8,721,998 | $1.33 |
| Pfizer | 8,162,821 | $25.00 |
| Mobile-health Network Solutions | 7,176,915 | $3.93 |
| Incannex Healthcare | 5,949,185 | $0.32 |
| Recursion | 4,317,953 | $4.06 |
| Exact Sciences | 3,078,853 | $100.95 |
| Shuttle Pharmaceuticals | 3,040,004 | $1.93 |
| Applied Therapeutics | 2,345,691 | $0.26 |
| Nano-X Imaging | 2,332,768 | $4.25 |
| Novo Nordisk | 1,970,807 | $47.10 |
| Adial Pharmaceuticals | 1,818,762 | $0.29 |
| Merck | 1,638,765 | $96.50 |
| Pasithea Therapeutics | 1,626,037 | $0.32 |
| agilon health | 1,394,579 | $0.57 |
| Clover Health | 1,319,693 | $2.26 |
| Quantum-Si | 1,311,001 | $1.24 |
| Moderna | 1,289,206 | $23.09 |
| Plus Therapeutics | 1,246,332 | $0.50 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
